1. Home
  2. GTY vs GENB Comparison

GTY vs GENB Comparison

Compare GTY & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Getty Realty Corporation

GTY

Getty Realty Corporation

HOLD

Current Price

$33.07

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

GENB

Generate Biomedicines Inc. Common Stock

N/A

Current Price

$12.94

Market Cap

1.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
GTY
GENB
Founded
1955
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.9B
IPO Year
1998
N/A

Fundamental Metrics

Financial Performance
Metric
GTY
GENB
Price
$33.07
$12.94
Analyst Decision
Buy
Strong Buy
Analyst Count
5
6
Target Price
$32.60
$23.20
AVG Volume (30 Days)
334.1K
812.6K
Earning Date
04-22-2026
05-11-2026
Dividend Yield
5.92%
N/A
EPS Growth
8.00
N/A
EPS
0.43
N/A
Revenue
$221,727,000.00
N/A
Revenue This Year
$9.39
N/A
Revenue Next Year
$7.83
$16.58
P/E Ratio
$76.70
N/A
Revenue Growth
9.02
N/A
52 Week Low
$25.39
$11.00
52 Week High
$34.75
$16.75

Technical Indicators

Market Signals
Indicator
GTY
GENB
Relative Strength Index (RSI) 54.82 46.20
Support Level $32.44 $11.63
Resistance Level $33.99 $13.76
Average True Range (ATR) 0.66 1.31
MACD -0.02 -0.12
Stochastic Oscillator 72.84 19.76

Price Performance

Historical Comparison
GTY
GENB

About GTY Getty Realty Corporation

Getty Realty Corp is a net lease real estate investment trust in the U.S.A, specializing in the acquisition, financing, and development of convenience, automotive, and other single-tenant retail real estate. The company's portfolio includes convenience stores, express tunnel car washes, automotive service centers (gasoline and repair, oil and maintenance, tire and battery, and collision), drive-thru quick service restaurants, and certain other freestanding retail properties. It generates maximum revenue in the form of rental income.

About GENB Generate Biomedicines Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Share on Social Networks: